Literature DB >> 27358803

High mortality in tuberculosis patients despite HIV interventions in Swaziland.

G Mchunu1, J van Griensven2, S G Hinderaker3, W Kizito4, W Sikhondze1, M Manzi5, T Dlamini1, A D Harries6.   

Abstract

SETTING: All health facilities providing tuberculosis (TB) care in Swaziland.
OBJECTIVE: To describe the impact of human immunodeficiency virus (HIV) interventions on the trend of TB treatment outcomes during 2010-2013 in Swaziland; and to describe the evolution in TB case notification, the uptake of HIV testing, antiretroviral therapy (ART) and cotrimoxazole preventive therapy (CPT), and the proportion of TB-HIV co-infected patients with adverse treatment outcomes, including mortality, loss to follow-up and treatment failure.
DESIGN: A retrospective descriptive study using aggregated national TB programme data.
RESULTS: Between 2010 and 2013, TB case notifications in Swaziland decreased by 40%, HIV testing increased from 86% to 96%, CPT uptake increased from 93% to 99% and ART uptake among TB patients increased from 35% to 75%. The TB-HIV co-infection rate remained around 70% and the proportion of TB-HIV cases with adverse outcomes decreased from 36% to 30%. Mortality remained high, at 14-16%, over the study period, and anti-tuberculosis treatment failure rates were stable over time (<5%).
CONCLUSION: Despite high CPT and ART uptake in TB-HIV patients, mortality remained high. Further studies are required to better define high-risk patient groups, understand the reasons for death and design appropriate interventions.

Entities:  

Keywords:  Swaziland; antiretroviral treatment; mortality; operational research; tuberculosis

Year:  2016        PMID: 27358803      PMCID: PMC4913672          DOI: 10.5588/pha.15.0081

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  18 in total

Review 1.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

2.  Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland.

Authors:  Elisabeth Sanchez-Padilla; Matthias Merker; Patrick Beckert; Frauke Jochims; Themba Dlamini; Patricia Kahn; Maryline Bonnet; Stefan Niemann
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

3.  Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals.

Authors:  Maunank Shah; Willy Ssengooba; Derek Armstrong; Lydia Nakiyingi; Molly Holshouser; Jerrold J Ellner; Moses Joloba; Yukari C Manabe; Susan E Dorman
Journal:  AIDS       Date:  2014-06-01       Impact factor: 4.177

4.  What has Karonga taught us? Tuberculosis studied over three decades.

Authors:  A C Crampin; J R Glynn; P E M Fine
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

5.  Declining tuberculosis notification trend associated with strengthened TB and expanded HIV care in Swaziland.

Authors:  S Haumba; T Dlamini; M Calnan; V Ghazaryan; A E Smith-Arthur; P Preko; P Ehrenkranz
Journal:  Public Health Action       Date:  2015-05-08

6.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Authors:  Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

7.  Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis.

Authors:  Kelly E Dooley; Tania Tang; Jonathan E Golub; Susan E Dorman; Wendy Cronin
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

8.  Timing, rates, and causes of death in a large South African tuberculosis programme.

Authors:  Nigel Field; Megan S C Lim; Jill Murray; Robert J Dowdeswell; Judith R Glynn; Pam Sonnenberg
Journal:  BMC Infect Dis       Date:  2014-12-21       Impact factor: 3.090

Review 9.  HIV treatment cascade in tuberculosis patients.

Authors:  Richard J Lessells; Soumya Swaminathan; Peter Godfrey-Faussett
Journal:  Curr Opin HIV AIDS       Date:  2015-11       Impact factor: 4.283

Review 10.  Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.

Authors:  Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich
Journal:  PLoS Med       Date:  2012-07-24       Impact factor: 11.069

View more
  4 in total

1.  Risk factors for mortality in TB patients: a 10-year electronic record review in a South African province.

Authors:  J Christo Heunis; N Gladys Kigozi; Perpetual Chikobvu; Sonja Botha; Hcj Dingie van Rensburg
Journal:  BMC Public Health       Date:  2017-01-06       Impact factor: 3.295

2.  Hyperglycemia and Risk of All-cause Mortality Among People Living With HIV With and Without Tuberculosis Disease in Myanmar (2011-2017).

Authors:  Nang Thu Thu Kyaw; Srinath Satyanarayana; Htun Nyunt Oo; Ajay M V Kumar; Anthony D Harries; Si Thu Aung; Khine Wut Yee Kyaw; Khaing Hnin Phyo; Thet Ko Aung; Matthew J Magee
Journal:  Open Forum Infect Dis       Date:  2018-12-28       Impact factor: 3.835

3.  Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis.

Authors:  Bernhard Kerschberger; Michael Schomaker; Alex Telnov; Debrah Vambe; Nicholas Kisyeri; Welile Sikhondze; Lorraine Pasipamire; Siphiwe Mavis Ngwenya; Barbara Rusch; Iza Ciglenecki; Andrew Boulle
Journal:  Trop Med Int Health       Date:  2019-08-07       Impact factor: 2.622

4.  Standard precautions for preventing Tuberculosis and HIV: Compliance of Eswatini university student nurses.

Authors:  Ncobile Sidzandza Victoria Gina; Melitah Molatelo Rasweswe; Miriam Mmamphamo Moagi
Journal:  PLoS One       Date:  2021-12-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.